Haruki Momma1, Kaijun Niu, Yoritoshi Kobayashi, Cong Huang, Masahiko Chujo, Atsushi Otomo, Hiroko Tadaura, Toshio Miyata, Ryoichi Nagatomi. 1. Division of Biomedical Engineering for Health and Welfare (H.M., R.N.), Graduate School of Biomedical Engineering, and Department of Medicine and Science in Sports and Exercise (Y.K., C.H., M.C., A.O.), United Centers for Advanced Research and Translational Medicine (T.M.), Graduate School of Medicine, Tohoku University, Sendai 980-8575, Japan; Department of Epidemiology (K.N.), School of Public Health, Tianjin Medical University, Tianjin 300192, People's Republic of China; and School of Nursing (H.T.) Miyagi University, Sendai 989-3126, Japan.
Abstract
CONTEXT: Receptor for advanced glycation end products (RAGE) activation by its ligands is implicated in obesity-related metabolic disease and accelerated atherothrombosis. Circulating soluble (sRAGE) and/or endogenous secretory RAGE (esRAGE) may counteract the detrimental effects of RAGE. OBJECTIVE: This study aimed at determining the relationship between circulating RAGE and metabolic syndrome (MetS) incidence among Japanese adult men. METHODS: This 2-year longitudinal study included 426 Japanese men aged 30-83 years who had no MetS at baseline. Serum esRAGE and sRAGE were assayed by ELISA at baseline. Incident metabolic syndrome, defined according to the Asian cutoff based on the 2009 criteria of the American Heart Association Scientific Statements, was evaluated after the 2-year follow-up. RESULTS: During the follow-up period, 55 participants (12.9%) had newly diagnosed MetS. In the multiple logistic models comparing MetS risk in the lowest with that in the highest tertile of baseline esRAGE, a high serum esRAGE level was found to be significantly associated with a low risk of MetS [odds ratios (95% confidence interval), 0.37 (0.14-0.95); P for trend = 0.038] after adjusting for lifestyle and sociodemographic factors, serum high-sensitivity C-reactive protein level, estimated glomerular filtration rate, and MetS components at baseline. Although sRAGE and esRAGE were strongly correlated (r(s) = 0.88), the sRAGE level was not associated with MetS incidence. CONCLUSIONS: A high circulating esRAGE level, but not sRAGE level, was associated with a low MetS incidence among Japanese adult men.
CONTEXT: Receptor for advanced glycation end products (RAGE) activation by its ligands is implicated in obesity-related metabolic disease and accelerated atherothrombosis. Circulating soluble (sRAGE) and/or endogenous secretory RAGE (esRAGE) may counteract the detrimental effects of RAGE. OBJECTIVE: This study aimed at determining the relationship between circulating RAGE and metabolic syndrome (MetS) incidence among Japanese adult men. METHODS: This 2-year longitudinal study included 426 Japanese men aged 30-83 years who had no MetS at baseline. Serum esRAGE and sRAGE were assayed by ELISA at baseline. Incident metabolic syndrome, defined according to the Asian cutoff based on the 2009 criteria of the American Heart Association Scientific Statements, was evaluated after the 2-year follow-up. RESULTS: During the follow-up period, 55 participants (12.9%) had newly diagnosed MetS. In the multiple logistic models comparing MetS risk in the lowest with that in the highest tertile of baseline esRAGE, a high serum esRAGE level was found to be significantly associated with a low risk of MetS [odds ratios (95% confidence interval), 0.37 (0.14-0.95); P for trend = 0.038] after adjusting for lifestyle and sociodemographic factors, serum high-sensitivity C-reactive protein level, estimated glomerular filtration rate, and MetS components at baseline. Although sRAGE and esRAGE were strongly correlated (r(s) = 0.88), the sRAGE level was not associated with MetS incidence. CONCLUSIONS: A high circulating esRAGE level, but not sRAGE level, was associated with a low MetS incidence among Japanese adult men.
Authors: Pia S Petersen; Xia Lei; Marcus M Seldin; Susana Rodriguez; Mardi S Byerly; Andrew Wolfe; Scott Whitlock; G William Wong Journal: Am J Physiol Regul Integr Comp Physiol Date: 2014-10-15 Impact factor: 3.619
Authors: Barry I Hudson; Chuanhui Dong; Hannah Gardener; Mitchell S V Elkind; Clinton B Wright; Ron Goldberg; Ralph L Sacco; Tatjana Rundek Journal: Metabolism Date: 2014-06-04 Impact factor: 8.694
Authors: Claire K Inman; Abdullah Aljunaibi; Hyunwook Koh; Abdishakur Abdulle; Raghib Ali; Abdullah Alnaeemi; Eiman Al Zaabi; Naima Oumeziane; Marina Al Bastaki; Mohammed Al-Houqani; Fatma Al-Maskari; Ayesha Al Dhaheri; Syed M Shah; Laila Abdel Wareth; Wael Al Mahmeed; Habiba Alsafar; Fatme Al Anouti; Ayesha Al Hosani; Muna Haji; Divya Galani; Matthew J O'Connor; Jiyoung Ahn; Tomas Kirchhoff; Scott Sherman; Richard B Hayes; Huilin Li; Ravichandran Ramasamy; Ann Marie Schmidt Journal: J Clin Transl Endocrinol Date: 2017-08-14